BCA
MDGL icon

Berman Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Berman Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Sell
5
-4
-44% -$346 ﹤0.01% 2154
2021
Q2 		$0 Buy
+9
New +$1.06K ﹤0.01% 1979

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's MDGL Position: Q3 2021 in Review

Berman Capital Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 44% in Q3 2021, selling an estimated $346 and leaving 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Berman Capital Advisors first reported a position in MDGL in Q2 2021 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold MDGL as of Q3 2021.

  • Berman Capital Advisors held 5 shares of Madrigal Pharmaceuticals worth $0 as of Q3 2021.
  • Berman Capital Advisors sold 4 Madrigal Pharmaceuticals shares in Q3 2021, an estimated $346.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2154 holding.
  • Berman Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.